Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro,

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans Tuesday to file two lawsuits and send about fifty cease-and-desist letters.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let’s take a look at how both drugs tackle type 2 diabetes.

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major weight loss. Price & details here.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of blockbuster treatments, Mounjaro and Zepbound.